Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the orphanet database. Eur J Hum Genet. 2020;28(2):165–73.
Benito-Lozano J, López-Villalba B, Arias-Merino G, De la PosadaPaz M, Alonso-Ferreira V. Diagnostic delay in rare diseases: data from the Spanish rare diseases patient registry. Orphanet J Rare Dis. 2022;17(1):418.
Michaels-Igbokwe C, McInnes B, MacDonald KV, Currie GR, Omar F, Shewchuk B, Bernier FP, Marshall DA. (Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta. Canada Genet Med. 2021;23(2):272–9.
Siegel IJ, Vaithilingam SL, Hartig MM, Patty EC, Mantsch LE, Garrison SR. Diagnostic delays in rare genetic disorders with neuropsychiatric manifestations: a systematic review. Eur J Med Genet. 2025;75: 105016.
Tinker RJ, Fisher M, Gimeno AF, Gill K, Ivey C, Peterson JF, Bastarache L. Diagnostic delay in monogenic disease: a scoping review. Genet Med. 2024;26(4): 101074.
Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, Elliott EJ, Group ARDIoFS. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12(1): 68.
Tisdale A, Cutillo CM, Nathan R, Russo P, Laraway B, Haendel M, Nowak D, Hasche C, Chan CH, Griese E, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16(1): 429.
Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163.
Garrison SR, Kennedy A, Manetto N, Pariser AR, Rutter JL, Yang G. The Economic Burden Of Rare Diseases: Quantifying The Sizeable Collective Burden And Offering Solutions. Health Affairs 2022.
Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med. 2021;23(11):2194–201.
Bonnot O, Klunemann HH, Velten C, Torres Martin JV, Walterfang M. Systematic review of psychiatric signs in Niemann-Pick disease type C. World J Biol Psychiatry. 2019;20(4):320–32.
Stark Z, Dolman L, Manolio TA, Ozenberger B, Hill SL, Caulfied MJ, Levy Y, Glazer D, Wilson J, Lawler M, et al. Integrating genomics into healthcare: a global responsibility. Am J Hum Genet. 2019;104(1):13–20.
Baum ML, Widge AS, Carpenter LL, McDonald WM, Cohen BM, Nemeroff CB, American Psychiatric Association Workgroup on B, Novel T. Pharmacogenomic clinical support tools for the treatment of depression. Am J Psychiatry. 2024;181(7):591–607.
Food, Administration D. FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. http://wwwfdagov/bbs/topics/news/2004/NEW01124html 2004.
Dyar B, Meaddough E, Sarasua SM, Rogers C, Phelan K, Boccuto L. Genetic findings as the potential basis of personalized pharmacotherapy in Phelan-McDermid syndrome. Genes. 2021. https://doi.org/10.3390/genes12081192.
Srivastava S, Sahin M, Buxbaum JD, Berry-Kravis E, Soorya LV, Thurm A, Bernstein JA, Asante-Otoo A, Bennett WE Jr, Betancur C, et al. Updated consensus guidelines on the management of Phelan-McDermid syndrome. Am J Med Genet A. 2023;191(8):2015–44.
Uhlenbusch N, Swaydan J, Holler A, Lowe B, Depping MK. Affective and anxiety disorders in patients with different rare chronic diseases: a systematic review and meta-analysis. Psychol Med. 2021. https://doi.org/10.1017/S0033291721003792.
Orphanet. Free datasets powered by Orphanet. In.;2022.
McKusick VA. Mendelian inheritance in Man and its online version, OMIM. Am J Hum Genet. 2007;80(4):588–604.
HCUP National Inpatient Sample (NIS). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019
HCUP Kids’ Inpatient Database (KID). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019.
HCUP National Readmissions Database (NRD). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019.
HCUP Nationwide Emergency Department Sample (NEDS). In. Edited by Quality AfHRa. Agency for Healthcare Research and Quality, Rockville, MD;2019.
Wu AC, McMahon P, Lu C. Ending the diagnostic odyssey-is whole-genome sequencing the answer? JAMA Pediatr. 2020;174(9):821–2.
de Vasconcelos P, Lacerda JF. Hematopoietic stem cell transplantation for neurological disorders: a focus on inborn errors of metabolism. Front Cell Neurosci. 2022;16: 895511.
Kartha RV, Zhou J, Basso L, Schroder H, Orchard PJ, Cloyd J. Mechanisms of antioxidant induction with high-dose N-acetylcysteine in childhood cerebral adrenoleukodystrophy. CNS Drugs. 2015;29(12):1041–7.
Fumagalli F, Calbi V, Natali Sora MG, Sessa M, Baldoli C, Rancoita PMV, Ciotti F, Sarzana M, Fraschini M, Zambon AA, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022;399(10322):372–83.
Costei C, Barbarosie M, Bernard G, Brais B, La Piana R. Adult hereditary white matter diseases with psychiatric presentation: clinical pointers and MRI algorithm to guide the diagnostic process. J Neuropsychiatry Clin Neurosci. 2021;33(3):180–93.
Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, Poll-The BT. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51.
Rosebush PI, Garside S, Levinson AJ, Mazurek MF. The neuropsychiatry of adult-onset adrenoleukodystrophy. J Neuropsychiatry Clin Neurosci. 1999;11(3):315–27.
van Geel BM, Assies J, Wanders RJ, Barth PG. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry. 1997;63(1):4–14.
Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H. Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers. Orphanet J Rare Dis. 2019;14(1):89.
Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol. 1992;49(4):401–6.
Shaimardanova AA, Chulpanova DS, Solovyeva VV, Mullagulova AI, Kitaeva KV, Allegrucci C, Rizvanov AA. Metachromatic leukodystrophy: diagnosis, modeling, and treatment approaches. Front Med (Lausanne). 2020;7: 576221.
Fraidakis MJ. Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry. 2013;3(9): e302.
Wong JC, Walsh K, Hayden D, Eichler FS. Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. J Inherit Metab Dis. 2018;41(4):647–56.
Bassuk AG, Joshi A, Burton BK, Larsen MB, Burrowes DM, Stack C. Alexander disease with serial MRS and a new mutation in the glial fibrillary acidic protein gene. Neurology. 2003;61(7):1014–5.
Prust M, Wang J, Morizono H, Messing A, Brenner M, Gordon E, Hartka T, Sokohl A, Schiffmann R, Gordish-Dressman H, et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology. 2011;77(13):1287–94.
van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol. 2017;134(3):351–82.
Tsuyusaki Y, Shimbo H, Wada T, Iai M, Tsuji M, Yamashita S, Aida N, Kure S, Osaka H. Paradoxical increase in seizure frequency with valproate in nonketotic hyperglycinemia. Brain Dev. 2012;34(1):72–5.
Subramanian V, Kadiyala P, Hariharan P, Neeraj E. A rare case of glycine encephalopathy unveiled by valproate therapy. J Pediatr Neurosci. 2015;10(2):143–5.
Walterfang M, Fietz M, Fahey M, Sullivan D, Leane P, Lubman DI, Velakoulis D. The neuropsychiatry of Niemann-Pick type C disease in adulthood. J Neuropsychiatry Clin Neurosci. 2006;18(2):158–70.
Golechha GR, Chatterjee SB, Sethi BB, Agarwal SS. Acute porphyria amongst psychiatric patients. Indian J Psychiatry. 1981;23(4):365–9.
Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161–78.
Rinaldi B, Villa R, Sironi A, Garavelli L, Finelli P, Bedeschi MF. Smith-Magenis syndrome-clinical review, biological background and related disorders. Genes. 2022. https://doi.org/10.3390/genes13020335.
Rozensztrauch A, Sebzda A, Smigiel R. Clinical presentation of Rett syndrome in relation to quality of life and family functioning. J Int Med Res. 2021;49(4): 3000605211007714.
Lindsay S, Splitt M, Edney S, Berney TP, Knight SJ, Davies KE, O’Brien O, Gale M, Burn J. PPM-X: a new X-linked mental retardation syndrome with psychosis, pyramidal signs, and macroorchidism maps to Xq28. Am J Hum Genet. 1996;58(6):1120–6.
Lambert S, Maystadt I, Boulanger S, Vrielynck P, Destree A, Lederer D, Moortgat S. Expanding phenotype of p.Ala140Val mutation in MECP2 in a 4 generation family with X-linked intellectual disability and spasticity. Eur J Med Genet. 2016;59(10):522–5.
Cohen D, Lazar G, Couvert P, Desportes V, Lippe D, Mazet P, Heron D. MECP2 mutation in a boy with language disorder and schizophrenia. Am J Psychiatry. 2002;159(1):148–9.
Savatt JM, Myers SM. Genetic testing in neurodevelopmental disorders. Front Pediatr. 2021;9: 526779.
Srivastava S, Love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, Firth HV, Frazier T, Hansen RL, Prock L, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413–21.
Gordon-Smith K, Jones LA, Burge SM, Munro CS, Tavadia S, Craddock N. The neuropsychiatric phenotype in Darier disease. Br J Dermatol. 2010;163(3):515–22.
Van Den Bossche MJ, Van Wallendael KL, Strazisar M, Sabbe B, Del-Favero J. Co-occurrence of Marfan syndrome and schizophrenia: what can be learned? Eur J Med Genet. 2012;55(4):252–5.
Mechri A, Mard A, Zaafrane F. Paranoid schizophrenia in a woman with Marfan syndrome. Tunis Med. 2017;95(2):157–8.
Romano J, Linares RL. Marfan’s syndrome and schizophrenia: a case report. Arch Gen Psychiatry. 1987;44(2):190–2.
Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, Olfson M, Potkin SG, Correll CU. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry 2019;80(2).
Albert U, Bergesio C, Pessina E, Maina G, Bogetto F. Management of treatment resistant obsessive-compulsive disorder. Algorit#hms for pharmacotherapy. Panminerva Med. 2002;44(2):83–91.
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros-Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, et al. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013;30(8):716–22.
Walkowiak D, Domaradzki J. Are rare diseases overlooked by medical education? Awareness of rare diseases among physicians in Poland: an explanatory study. Orphanet J Rare Dis. 2021;16(1): 400.
Therapies SHG: Rare Disease Impact Report: Insights from patients and the medical community. Shire Human Genetic Therapies, Tech Rep 2013.
Sriretnakumar V, Harripaul R, Kennedy JL, So J. When rare meets common: treatable genetic diseases are enriched in the general psychiatric population. Am J Med Genet A. 2024. https://doi.org/10.1002/ajmg.a.63609.
Lunke S, Bouffler SE, Patel CV, Sandaradura SA, Wilson M, Pinner J, Hunter MF, Barnett CP, Wallis M, Kamien B, et al. Integrated multi-omics for rapid rare disease diagnosis on a national scale. Nat Med. 2023;29(7):1681–91.
Thorpe E, Williams T, Shaw C, Chekalin E, Ortega J, Robinson K, Button J, Jones MC, Campo MD, Basel D, et al. The impact of clinical genome sequencing in a global population with suspected rare genetic disease. Am J Hum Genet. 2024;111(7):1271–81.